Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib with Anastrozole or Fulvestrant in Metastatic Breast Cancer
NCT00057941Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2003
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gefitinib in breast cancer (2 arms), sponsored by National Cancer Institute. Primary endpoint: Clinical Benefit Rate at 3 years. Started Sep 2003; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00057941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00057941.